Pathways to drug development for autism spectrum disorders.
about
Therapeutic role of hematopoietic stem cells in autism spectrum disorder-related inflammationBrain functional networks in syndromic and non-syndromic autism: a graph theoretical study of EEG connectivity.Autism spectrum disorders and neuropathology of the cerebellumUse of transcranial magnetic stimulation in autism spectrum disordersFMRP Expression Levels in Mouse Central Nervous System Neurons Determine Behavioral Phenotype.The BOLD signal and neurovascular coupling in autismUpdated report on tools to measure outcomes of clinical trials in fragile X syndrome.Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice.Persistent astrocyte activation in the fragile X mouse cerebellumFocal brain inflammation and autism.Neurobiologically-based treatments in Rett syndrome: opportunities and challenges.The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders.Disruption of the ASTN2/TRIM32 locus at 9q33.1 is a risk factor in males for autism spectrum disorders, ADHD and other neurodevelopmental phenotypes.What's hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders.mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders.Pharmacogenomic medicine in autism: challenges and opportunities.Sensitivity of the modified Children's Yale-Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials.Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile miceTranscranial magnetic stimulation (TMS) therapy for autism: an international consensus conference held in conjunction with the international meeting for autism research on May 13th and 14th, 2014.Defining the hidden evidence in autism research. Forty per cent of rigorously designed clinical trials remain unpublished - a cross-sectional analysis.Delayed myelination in a mouse model of fragile X syndrome.
P2860
Q21131214-344986F7-8819-46A0-9A31-19C8DBA972AAQ21245286-CEA836CB-1392-4A95-889D-9EC6BCD2BA5EQ26853603-5080369E-FFD0-41CD-8761-8859CCF66A8AQ28300252-48E5D051-0634-4D99-AF10-930A7C4E179CQ30365865-E4D2C25C-29BC-4DA2-9726-F3B892B4715EQ30659465-BD9D54BC-BF67-4678-AD1F-341E82DEB6CBQ33785978-B197A43E-9615-4C29-BA67-7E0CBF04AB60Q34499370-AEF5A1CB-E11D-4966-9698-92764866C262Q36186534-1C401B63-D212-4188-90C6-D98B93F1C7A5Q36766675-5BBDF5B2-FE7B-44CD-83EE-ACF6C367938CQ37558440-31156211-C258-4039-9E60-12F3291450E5Q37598422-D74ADF3F-769B-4A61-B4E9-D7E836103F86Q37708396-618B2C4F-636A-4844-A09E-097CF5B4A876Q38038399-7298352C-F0C9-4AB5-9DA4-ED5F4EB64FC3Q38046662-B50E44E4-2D1E-4170-8F94-5953533A77BFQ38270928-A7110BEB-F642-4EF3-A9D3-811FB5FA2540Q41060924-00682C56-7A65-4E31-8CD9-F0A1521259F6Q41918439-AC3A7A8C-3A01-45AC-BD18-0420E545CCA3Q42096144-2E5E7243-4DF9-4CBC-A850-BE3D69561725Q47874564-996C04E3-ED2A-4A16-AB83-B2FDC78757D0Q50313070-E64689F9-BD9E-452B-827F-AADECF2CE19E
P2860
Pathways to drug development for autism spectrum disorders.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pathways to drug development for autism spectrum disorders.
@en
Pathways to drug development for autism spectrum disorders.
@nl
type
label
Pathways to drug development for autism spectrum disorders.
@en
Pathways to drug development for autism spectrum disorders.
@nl
prefLabel
Pathways to drug development for autism spectrum disorders.
@en
Pathways to drug development for autism spectrum disorders.
@nl
P2093
P2860
P356
P1476
Pathways to drug development for autism spectrum disorders.
@en
P2093
D R Hampson
L K K Pacey
S Gholizadeh
P2860
P304
P356
10.1038/CLPT.2011.245
P407
P577
2011-12-28T00:00:00Z